Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    March 2024
  1. DILLI BATCHA JS, Gota V, Matcha S, Raju AP, et al
    Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.
    Cancer Chemother Pharmacol. 2024 Mar 5. doi: 10.1007/s00280-024-04644.
    >> Share

  2. QU W, Lu J, Ji Y, He Z, et al
    Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2024 Mar 2. doi: 10.1007/s00280-024-04642.
    >> Share

    February 2024
  3. MARCELLETTI JF, Sikic BI
    Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.
    Cancer Chemother Pharmacol. 2024 Feb 26. doi: 10.1007/s00280-024-04656.
    >> Share

    October 2023
  4. BARNETT S, Nyein AC, Galler M, Jamieson D, et al
    Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin-Johnson syndrome: a case report.
    Cancer Chemother Pharmacol. 2023;92:325-328.
    >> Share

    August 2023
  5. HE S, Shao Q, Zhao J, Bian J, et al
    Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
    Cancer Chemother Pharmacol. 2023 Aug 25. doi: 10.1007/s00280-023-04581.
    >> Share

  6. MARCELLETTI JF, Sikic BI
    A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
    Cancer Chemother Pharmacol. 2023 Aug 21. doi: 10.1007/s00280-023-04578.
    >> Share

    July 2023
  7. KAGAN AB, Moses BS, Lapidus R, Mott BT, et al
    ART714 is a best-in-class antileukemic 2-carbon-linked dimeric artemisinin derivative.
    Cancer Chemother Pharmacol. 2023;92:39-50.
    >> Share

    May 2023
  8. SINGH M, Bhaskar D, Bhatia P, Thakur R, et al
    Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2023 May 31. doi: 10.1007/s00280-023-04546.
    >> Share

    April 2023
  9. KHERA S, Mahajan D, Barbind K, Dhingra S, et al
    Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study.
    Cancer Chemother Pharmacol. 2023;91:331-336.
    >> Share

    March 2023
  10. MONTESINOS P, Kota V, Brandwein J, Bousset P, et al
    A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2023 Mar 9:1-6. doi: 10.1007/s00280-023-04516.
    >> Share

  11. SHAFER D, Kagan AB, Rudek MA, Kmieciak M, et al
    Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
    Cancer Chemother Pharmacol. 2023;91:281-290.
    >> Share

  12. DONNETTE M, Osanno L, Giocanti M, Venton G, et al
    Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients.
    Cancer Chemother Pharmacol. 2023;91:231-238.
    >> Share

    December 2022
  13. LI M, Kong XY, Wang SM
    Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2022 Dec 4. doi: 10.1007/s00280-022-04498.
    >> Share

  14. JOHNSON S, Dhamne C, Sankaran H, Gandhi KA, et al
    A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL).
    Cancer Chemother Pharmacol. 2022;90:445-453.
    >> Share

    November 2022
  15. JAISWAL A, Jaiswal A, Williamson EA, Gelfond J, et al
    Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis.
    Cancer Chemother Pharmacol. 2022 Nov 8. pii: 10.1007/s00280-022-04490.
    >> Share

    August 2022
  16. SATO H, Kobayashi T, Fujita N, Yamashita T, et al
    Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2022 Aug 13. pii: 10.1007/s00280-022-04460.
    >> Share

  17. ZHANG W, Liu J, Li Y, Guo F, et al
    A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.
    Cancer Chemother Pharmacol. 2022 Aug 12. pii: 10.1007/s00280-022-04462.
    >> Share

    June 2022
  18. LIAO LH, Chen YQ, Huang DP, Wang LN, et al
    The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Cancer Chemother Pharmacol. 2022 Jun 27. pii: 10.1007/s00280-022-04449.
    >> Share

  19. SECHAUD R, Sinclair K, Grosch K, Ouatas T, et al
    Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
    Cancer Chemother Pharmacol. 2022 Jun 25. pii: 10.1007/s00280-022-04448.
    >> Share

    March 2022
  20. FUKUDA N, Akamine Y, Abumiya M, Takahashi S, et al
    Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
    Cancer Chemother Pharmacol. 2022 Mar 22. pii: 10.1007/s00280-022-04419.
    >> Share

    February 2022
  21. RAMALINGAM R, Kaur H, Scott JX, Sneha LM, et al
    Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2022 Feb 14. pii: 10.1007/s00280-022-04405.
    >> Share

    January 2022
  22. LIU J, Luo W, Chen Q, Chen X, et al
    Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
    Cancer Chemother Pharmacol. 2022 Jan 23. pii: 10.1007/s00280-021-04385.
    >> Share

    November 2021
  23. YOSHIDA K, Fujita A, Narazaki H, Asano T, et al
    Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Cancer Chemother Pharmacol. 2021 Nov 26. pii: 10.1007/s00280-021-04373.
    >> Share

  24. TONG WH
    Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase".
    Cancer Chemother Pharmacol. 2021;88:919-920.
    >> Share

    October 2021
  25. PANETTA JC, Liu Y, Bottiglieri T, Arning E, et al
    Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Cancer Chemother Pharmacol. 2021;88:655-664.
    >> Share

    September 2021
  26. CONDORELLI A, Matteo C, Leotta S, Schinina G, et al
    Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.
    Cancer Chemother Pharmacol. 2021 Sep 29. pii: 10.1007/s00280-021-04356.
    >> Share

    July 2021
  27. GOTO H, Yoshino Y, Ito M, Nagai J, et al
    Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 Jul 18. pii: 10.1007/s00280-021-04321.
    >> Share

    June 2021
  28. TOKSVANG LN, Andres-Jensen L, Rank CU, Niinimaki R, et al
    Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Jun 18. pii: 10.1007/s00280-021-04316.
    >> Share

    May 2021
  29. YOUSSEF YH, Makkeyah SM, Soliman AF, Meky NH, et al
    Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 May 7. pii: 10.1007/s00280-021-04290.
    >> Share

    April 2021
  30. NIELSEN SN, Toksvang LN, Grell K, Nersting J, et al
    No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Apr 29. pii: 10.1007/s00280-021-04281.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016